ASH 2017 | PEP-C for lymphoma palliative care: a regional experience in the UK
George Follows
Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is a chemotherapy regimen used with palliative intent in these patients. Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the retrospective study of PEP-C use in relapsed/refractory lymphoma patients over an 8-year period. The data will allow for physicians to use this utilize this regimen and improve patients’ quality of life during the end-of-life phase. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Similar topics
Related videos

Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo

Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

Waldenström’s macroglobulinemia: a link between institution visited and survival
Stephen Ansell

A historical transition in cancer therapy
Christian Chabannon
9th December 2017
More from George Follows